Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ: ACXP · Real-Time Price · USD
5.31
+0.59 (12.57%)
Aug 25, 2025, 4:00 PM - Market closed

Acurx Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2020
Selling, General & Admin
6.98.78.537.3410.782.4
Upgrade
Research & Development
3.155.46.044.752.032.2
Upgrade
Operating Expenses
10.0514.114.5812.0912.814.6
Upgrade
Operating Income
-10.05-14.1-14.58-12.09-12.81-4.6
Upgrade
EBT Excluding Unusual Items
-10-14.1-14.58-12.09-12.81-4.6
Upgrade
Other Unusual Items
----0.07-
Upgrade
Pretax Income
-10-14.1-14.58-12.09-12.75-4.6
Upgrade
Net Income
-10-14.1-14.58-12.09-12.75-4.6
Upgrade
Net Income to Common
-10-14.1-14.58-12.09-12.75-4.6
Upgrade
Shares Outstanding (Basic)
111100
Upgrade
Shares Outstanding (Diluted)
111100
Upgrade
Shares Change (YoY)
32.55%27.56%17.15%26.72%37.88%30.29%
Upgrade
EPS (Basic)
-10.37-17.45-23.01-22.36-29.87-14.86
Upgrade
EPS (Diluted)
-10.37-17.45-23.01-22.36-29.87-14.86
Upgrade
EBIT
-10.05-14.1-14.58-12.09-12.81-4.6
Upgrade
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q